🔥 Premium AI-powered Stock Picks from InvestingPro Now up to 50% OffCLAIM SALE

Amgen reports major reduction in IgG4-RD flares in phase 3 trial

EditorBrando Bricchi
Published 2024/06/05, 18:58
AMGN
-

THOUSAND OAKS, Calif. - Amgen (NASDAQ:AMGN) has announced the successful completion of a Phase 3 clinical trial for UPLIZNA® (inebilizumab-cdon), demonstrating a significant reduction in flares for patients with Immunoglobulin G4-related disease (IgG4-RD). The trial, which is the first randomized, placebo-controlled study of its kind for IgG4-RD, met its primary endpoint with an 87% reduction in the risk of flares compared to placebo.

During the 52-week trial period, all key secondary endpoints were also achieved, including annualized flare rate and flare-free, treatment-free, and corticosteroid-free complete remission. The safety profile of UPLIZNA was consistent with previous findings, and no new safety concerns were identified. Detailed results from the study are expected to be presented at an upcoming medical conference.

IgG4-RD is a rare and chronic inflammatory condition that can affect multiple organs and lead to irreversible organ damage. The disease has been historically difficult to manage due to a lack of approved therapies. UPLIZNA, already approved for Neuromyelitis Optica Spectrum Disorder (NMOSD), is being evaluated for its potential to fill this treatment gap.

The MITIGATE trial, as the study is known, involved 135 adults across 80 sites in 22 countries. Participants had a history of multi-organ disease and were actively being treated with glucocorticoids at the time of screening. The trial included a 52-week placebo-controlled period, followed by an optional 3-year open-label treatment period and up to two years of safety follow-up after discontinuation.

Amgen plans to seek regulatory approval for UPLIZNA as a treatment for IgG4-RD in the U.S., followed by submissions in other key markets. The trial was supported by Mitsubishi Tanabe Pharma and Hansoh Pharma, with Mitsubishi Tanabe holding marketing authorization in several Asian countries and Hansoh Pharma acting as the exclusive licensee for China's mainland, Hong Kong, and Macau.

This news is based on a press release statement and represents a potential advancement in the treatment options available for patients with IgG4-RD.

InvestingPro Insights

Amgen (NASDAQ:AMGN) has recently made headlines with the success of its Phase 3 clinical trial for UPLIZNA®, positioning the company as a leading innovator in the biotechnology industry. As investors consider the implications of this development on Amgen's market position, several metrics and InvestingPro Tips can provide further insight into the company's financial health and investment potential.

InvestingPro Data highlights a robust financial profile, with Amgen boasting a market capitalization of $164.88 billion USD. The company's dedication to shareholder returns is evident through its impressive track record of raising dividends for 14 consecutive years, as noted in one of the InvestingPro Tips. This consistent performance is a sign of stability and commitment to investors. Additionally, Amgen's P/E ratio stands at 43.8, indicating a high earnings multiple which could suggest investor confidence in future growth prospects.

Revenue growth also remains strong, with the last twelve months as of Q1 2024 showing a 12.76% increase, reflecting the company's ability to expand its financial base amidst a competitive landscape. The gross profit margin during the same period is at a healthy 66.49%, underscoring Amgen's efficiency in managing its cost of goods sold and maintaining profitability.

An InvestingPro Tip worth noting is that Amgen is currently trading near its 52-week high, with the price at 93.22% of this peak. This could indicate a bullish sentiment among investors, especially in light of the recent clinical trial success. However, it is important for investors to consider whether the stock's current valuation fully captures its future growth potential.

For those interested in further analysis, there are additional InvestingPro Tips available at https://www.investing.com/pro/AMGN, providing a deeper dive into Amgen's performance and outlook. Subscribers can use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, gaining access to a wealth of information that can inform investment decisions. With 11 more InvestingPro Tips listed in InvestingPro, investors have ample resources to evaluate Amgen's position in the biotechnology sector and its potential as a long-term investment.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.